Absorbable Heart Stent Market Size, Share & Industry Analysis, By Product Type (Drug-Eluting Bioresorbable Stents/Scaffolds and Non-Drug-Eluting Bioresorbable Stents/Scaffolds), By Material (Polymer-Based [PLLA/PLA-Based Polymers, Tyrosine-Derived Polycarbonates and Others] and Metal-Based [Magnesium-Based, Iron-Based and Others]), By End User (Hospitals & ASCs, Specialty Clinics, and Others), and Regional Forecast, 2026-2034

The absorbable heart stent market size was valued at USD 165.0 million in 2025 and is projected to grow from USD 191.0 million in 2026 to USD 637.0 million by 2034, exhibiting a CAGR of 16.2% during the forecast period.

Absorbable heart stent is a temporary, mesh-like tube made of dissolvable material that opens blocked coronary arteries and is naturally absorbed by the body over time. The increasing prevalence of cardiovascular diseases, the growing advancements in bioresorbable scaffold technology, and the expansion of healthcare infrastructure are driving the adoption rate of these devices in the market. The increasing geriatric population is further increasing the demand for vascular procedures, thereby driving the adoption of the product and contributing to global market growth.

For instance, according to the 2024 data published by the Centers for Disease Control & Prevention (CDC), approximately 1 in 20 adults aged 20 and older in the U.S. suffered from coronary artery disease.

The increasing technological advancements in absorbable heart stents among the major players, such as Abbott and Teleflex Incorporated, are further contributing to the demand for the product in the market.

Absorbable Heart Stent Market Trends

Technological Advancements in Absorbable Heart Stent to Drive Product Demand

The continuous technological advancements in absorbable heart stents are anticipated to drive market growth by addressing the mechanical and safety limitations associated with earlier-generation bioresorbable scaffolds. Companies are developing advanced polymer-based scaffolds and next-generation magnesium-based scaffolds with improved radial strength, thinner struts, improved deliverability, controlled drug elution, and more predictable resorption profiles. These advancements are intended to offer adequate vessel support during the healing period while enabling the scaffold to gradually disappear, potentially restoring natural vessel movement and eliminating the presence of a permanent metallic implant.

Market Dynamics

Market Drivers

Download Free sample to learn more about this report.

Increasing Prevalence of Chronic Conditions to Drive Market Growth

The growing prevalence of chronic diseases, including cardiovascular diseases, among others, is expected to increase the need for continuous and remote patient monitoring solutions globally, further resulting in absorbable heart stent market growth. These conditions substantially increase the risk of coronary artery disease, atherosclerosis, myocardial infarction, and other cardiovascular complications that may ultimately require percutaneous coronary intervention (PCI). The increasing number of patients requiring coronary revascularization is resulting in growing demand for advanced coronary stenting technologies, including bioresorbable vascular scaffolds, in the market.

This, along with growing healthcare expenditure and development of healthcare infrastructure, is further driving the demand for these products in the market. Therefore, the factors above, along with the increasing focus of key companies on offering advanced products, are further anticipated to contribute to the global market expansion.

Market Restraints

High Cost Associated with Advanced Absorbable Heart Stent to Limit Market Growth

The high cost of product development and the requirement for extensive long-term clinical evidence are major restraints for the global market. Absorbable scaffolds must demonstrate not only immediate procedural efficacy and safety but also acceptable performance throughout the entire vessel-healing period and scaffold degradation. The key companies perform extensive feasibility studies, preclinical testing, imaging studies, large randomized controlled trials, and several years of post-implantation follow-up, resulting in higher product costs of the products. This, along with a limited reimbursement framework, makes adoption challenging for hospitals and healthcare settings with limited procurement budgets, thereby hampering market growth.

• For instance, according to the 2025 statistics published by Centers for Medicare and Medicaid Services (CMS), the retail price of the AGENT Paclitaxel-Coated Balloon Catheter is USD 5,500.

Market Opportunities

Expanding Percutaneous Coronary Intervention (PCI) Infrastructure to Drive Market Growth

The ongoing expansion of healthcare facilities in emerging countries, including Brazil and India, is resulting in increased capacity of cardiac catheterization laboratories, interventional cardiology centers, hospital infrastructure, among others. Increasing healthcare expenditure, government insurance programs, improved hospital accessibility, and increasing availability of trained interventional cardiologists are also contributing to PCI volumes. Additionally, public hospitals are adding cath labs to reduce procedure waiting times, further creating lucrative opportunities for manufacturers to strengthen their presence in the market.

• For instance, in February 2024, Koninklijke Philips N.V., a company in health technology, installed more than 1500 Cath Labs (interventional suites) in India.

Market Challenges

Limited Healthcare Access in Developing Countries to Hamper Market Growth

There is a growing demand for minimally invasive surgical procedures among the patient population. However, the limited availability of technologically advanced products, limited healthcare expenditure, coupled with inadequate reimbursement coverage, especially in developing countries, are resulting in limited access to healthcare facilities.

Furthermore, a limited number of healthcare facilities and professionals are contributing to delays in percutaneous coronary intervention (PCI) procedures, especially in emerging countries, including Mexico, China, and Brazil.

• For instance, according to 2023 data published by The World Bank Group (WBG), about 4.5 billion people were deprived of essential health services globally.

SEGMENTATION ANALYSIS

By Product Type

Increasing Advantages of Drug-Eluting Bioresorbable Stents/Scaffolds Boosted the Segmental Growth

To know how our report can help streamline your business, Speak to Analyst

Based on product type, the market is classified into drug-eluting bioresorbable stents/scaffolds and non-drug-eluting bioresorbable stents/scaffolds.

The drug-eluting bioresorbable stents/scaffolds segment held the largest absorbable heart stent market share in 2025. The growth is due to the growing advantages of drug-eluting bioresorbable stents/scaffolds, resulting in a growing number of PCI procedures worldwide. This, along with the increasing emphasis of key companies on launching drug-eluting bioresorbable stents/scaffolds, is further expected to contribute to the growth of the segment.

• For instance, according to a 2026 randomized trial published by the National Center for Biotechnology Information (NCBI), a thin-strut sirolimus-eluting iron bioresorbable scaffold was evaluated in 518 patients across 36 centers in China, and no scaffold thrombosis occurred in the bioresorbable scaffold group.

The non-drug-eluting bioresorbable stents/scaffolds segment is expected to grow at a CAGR of 25.0% over the forecast period.

By Material

Increasing Prevalence of Coronary Artery Disease Led to the Dominance of the Polymer-Based Segment

Based on material, the market is segmented into polymer-based and metal-based. Polymer-based segment is divided into PLLA/PLA-based polymers, tyrosine-derived polycarbonates, and others. Metal-based segment is bifurcated into magnesium-based, iron-based, and others.

The polymer-based segment dominated the global market, registering a share of 72.7% in 2025. The segment’s growth is due to the increasing prevalence of coronary artery disease and the advantages of polymer-based stents, including flexibility to optimize scaffold thickness, degradation rate, drug-loading capacity, radial support, and drug-release characteristics, resulting in an increasing demand for absorbable heart stents, thereby contributing to segmental growth.

• For instance, according to the 2023 data published by the Heart Foundation, approximately 590,000 people were affected by coronary heart disease in Australia.

The metal-based segment is set to flourish with a growth rate of 21.6% during the forecast period.

By End-user

Increasing Number of ASCs Encouraged the Hospitals & ASCs Segment Growth

Based on end user, the market is divided into hospitals & ASCs, specialty clinics, and others.

The hospitals & ASCs segment dominated the market in 2025. The increasing prevalence of chronic disorders and the growing number of PCI procedures in hospitals are some of the major factors contributing to the growth of the segment in the market. Furthermore, the segment is set to hold a 93.0% share in 2026.

• For instance, according to 2025 data published by Definitive Healthcare, it was reported that there were approximately 10,000 active ambulatory surgical centers in the U.S.

The specialty clinics segment is projected to grow at a CAGR of 18.8% during the forecast period.

Absorbable Heart Stent Market Regional Outlook

Based on region, the market has been studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America

To get more information on the regional analysis of this market, Download Free sample

North America is estimated to reach USD 0.7 million in 2026 in the market. The increasing prevalence of chronic conditions, growing number of hospitals & cath labs, and growing technological advancements in these absorbable heart stents, and growing Percutaneous Coronary Intervention (PCI) procedures are some of the factors contributing to the growth of the segment in the market.

• For instance, according to 2026 data published by the American Hospital Association (AHA), there were about 6,100 hospitals in the U.S.

U.S. Absorbable Heart Stent Market

Based on North America’s strong contribution and the U.S. dominance within the region, the U.S. market is expected to reach around USD 0.02 million in 2026, accounting for roughly 0.01% of global sales.

Europe

Europe is projected to record a growth rate of 12.9% during the forecast period, which is the second-highest among all regions, reaching a valuation of USD 68.8 million in 2026. The growing prevalence of chronic conditions and increasing adoption of absorbable heart stents are likely to contribute to market growth.

U.K. Absorbable Heart Stent Market

The U.K.’s market is estimated to reach around USD 6.9 million in 2026, representing roughly 3.6% of global revenues.

Germany Absorbable Heart Stent Market

Germany’s market is projected to reach approximately USD 11.4 million in 2026, equivalent to around 6.0% of global sales.

Asia Pacific

Asia Pacific market held the dominant share in 2024, valued at USD 79.9 million, and also maintained its leading share in 2025, reaching USD 94.9 million. The growing preference toward minimally invasive surgical procedures and increasing adoption of metal based stents are expected to contribute to the growth of the market. In the region, India and China are estimated to reach USD 16.1 million and USD 67.2 million, respectively, in 2026.

Japan Absorbable Heart Stent Market

The Japan market is estimated to reach around USD 4.7 million in 2026, accounting for roughly 2.4% of global revenues. Japan has historically reported a relatively high prevalence of chronic disorders, along with growing adoption of advanced technologies.

China Absorbable Heart Stent Market 

China’s market is projected to be one of the largest worldwide, with 2026 revenues standing at around USD 67.2 million, representing roughly 35.2% of global sales.

India Absorbable Heart Stent Market

The Indian market is estimated to reach around USD 16.1 million in 2026, accounting for roughly 8.4% of global revenues.

Latin America and Middle East & Africa

The Latin America and Middle East & Africa regions are expected to witness moderate growth in this market during the forecast period. The Latin America market is set to reach USD 5.9 million in 2026.  The growth is due to growing public healthcare investment and improved patient outcomes in the region. The Middle East & Africa market is also expected to grow due to the growing prevalence of cardiovascular conditions, including coronary artery diseases, and a growing number of cardiac specialty centers strengthening their presence in the market. In the Middle East & Africa, the GCC is set to reach a value of USD 2.6 million in 2026.

South Africa Absorbable Heart Stent Market

The South Africa market is projected to reach around USD 0.9 million in 2026, representing roughly 0.5% of global revenues.

Competitive Landscape

Key Industry Players

Key Players Focus on Publishing Study Results for Absorbable Heart Stent to Boost Their Market Presence

Abbott and Teleflex Incorporated were the major companies in the market in 2025. A robust and diversified product portfolio, along with a significant focus on strategic initiatives globally, is one of the key factors contributing to the dominance of these companies in the market. Moreover, the growing focus of key companies on publishing study results for absorbable heart stents to strengthen their market presence is likely to contribute to the market share.

• For instance, in September 2023, Biotronik published new data from the BIOMAG-I first-in-human trial that shed light on the vascular healing process following the implantation of DREAMS 3G, BIOTRONIK’s third-generation resorbable magnesium scaffold (RMS).

Other key players, including Boston Scientific Corporation, are also growing in the market, primarily due to their increasing focus on R&D activities to develop and introduce novel devices.

List of Key Absorbable Heart Stent Companies Profiled

• Teleflex Incorporated (Germany)
• Lepu Medical Technology (Beijing) Co., Ltd. (China)
• MicroPort Scientific Corporation (China)
• Shandong Huaan Biotechnology Co.,Ltd (China)
• Meril Life Sciences Private Limited (India)
• Reva Medical, LLC. (U.S.)
• Elixir Medical (U.S.)
• Abbott (U.S.)
• Biotyx Medical(Shenzhen)Co., Ltd. (China)
• Boston Scientific Corporation (U.S.)

KEY INDUSTRY DEVELOPMENTS

• June 2026: Teleflex Incorporated, a global provider of medical technologies, announced the beginning of enrollment in the BIOMAG‑III Study (NCT07258290), a landmark global study evaluating the Freesolve Resorbable Magnesium Scaffold (RMS).
• June 2026: Teleflex Incorporated, a global provider of medical technologies, announced the four‑year follow‑up data from the First-in-Human BIOMAG-I Clinical Study (NCT04157153) presented at the EuroPCR conference in Paris.
• July 2025: Teleflex Incorporated, a global provider of medical technologies, acquired substantially all of the Vascular Intervention business of BIOTRONIK SE & Co. KG. The acquisition adds a broad portfolio of therapeutic products to Teleflex’s portfolio of interventional access products, driving an enhanced global presence in the cath lab.
• April 2025: MicroPort Scientific Corporation presented Firesorb as a latest-generation fully bioresorbable cardiac stent at CMEF 2025 as part of its integrated cardiovascular portfolio.
• February 2024: Biotronik received CE approval and launched Freesolve Resorbable Magnesium Scaffold (RMS). This third-generation RMS has been engineered to provide optimized vessel support, yet achieves magnesium resorption within 12 months.

REPORT COVERAGE

The report provides a detailed global absorbable heart stent market analysis and focuses on key aspects such as leading companies and market segmentation, including product type, material, and end user. Besides this, the global report offers insights into the market trends and highlights key industry developments. In addition to the aforementioned factors, the report encompasses several factors that have contributed to the growth and advancement of the market over recent years.

Request for Customization   to gain extensive market insights.

Report Scope & Segmentation

Research Methodology

1. Bottom Up Approaches

Approach 1: Revenues and Market Share of Major BRS Players

• Collect BRS-specific or attributable revenue evidence from annual reports, SEC/HKEX filings, investor presentations, product portfolios, regulatory disclosures, and company websites.
• Map commercial status by product and geography; assign zero commercial revenue to pipeline or investigational products before launch.
• Estimate BRS revenue for NeoVas, XINSORB, Firesorb, MeRes100, Freesolve/Magmaris, Fantom Encore and other qualifying commercial products using disclosed sales, unit/implant evidence and manufacturer ASP assumptions.
• Adjust for ownership transfers and partnerships to prevent double counting - especially the July 2025 transfer of BIOTRONIK Vascular Intervention to Teleflex.
• Triangulate company estimates with product-level units, country penetration, and procurement evidence.

Approach 2: Product-Level Unit Sales and ASP Analysis

• Identify commercially launched branded BRS by country and year.
• Estimate annual implanted units using company disclosures, hospital coverage, procedure registries, and product-specific clinical/commercial milestones.
• Estimate manufacturer ASP separately from hospital/procurement price to avoid channel markup.
• Calculate product revenue = in-scope units x manufacturer ASP; aggregate by country and company.
• Perform sensitivity analysis on BRS penetration and ASP rather than forcing the model to match an external market-size benchmark.

Approach 3: PCI Procedure and Eligible-Lesion Model

• Assess annual PCI procedure volumes and coronary stent use in each scoped country.
• Map the procedure pool to BRS eligibility based on commercial product labeling, lesion complexity, and physician adoption.
• Apply BRS penetration by country, reflecting regulatory status and commercial availability.
• Estimate stents/scaffolds per treated PCI and multiply by manufacturer ASP.
• Aggregate country values to regional and global totals.

2. Top Down Approaches

Approach 1: Analysis of Parent Coronary Stent / PCI Addressable Market

• Start from country-level PCI and coronary stent demand, not from a third-party BRS market report.
• Estimate the proportion addressable by BRS after regulatory, lesion-selection, and physician-adoption constraints.
• Use permanent-DES pricing and procurement only as boundary/price-pressure evidence, not as BRS revenue.
• Compare the top-down result with company and unit-level bottom-up estimates.

3. List of Key Sources

• Company annual reports, SEC/HKEX filings, investor presentations, product pages and press releases.
• FDA, European Commission/MDR/EUDAMED, PMDA/MHLW, NMPA, CDSCO and TGA regulatory sources.
• OECD/Eurostat/ESC Atlas, China cardiovascular/NHSA data, AIHW and national PCI registries.
• gov and peer-reviewed clinical publications for scaffold safety, efficacy, and long-term follow-up.
• Government procurement/price-control records and hospital/tender evidence.
• ISO 13485 and quality-system references for manufacturing/regulatory analysis

4. Primary Interviews

Supply Side Interviews: 60%

• Key Respondents:
  • BRS/stent manufacturers and developers
  • Product, business-development and commercial leaders
  • Regulatory affairs and market-access professionals
  • Manufacturing, quality assurance and supply-chain executives
  • Specialty distributors and tender/procurement teams
  • Clinical-trial and medical-affairs teams

Demand Side Interviews: 40%

• Key Respondents:
  • Interventional cardiologists and high-volume PCI operators
  • Cath-lab directors and hospital cardiovascular service-line leaders
  • Hospital procurement and formulary/tender managers
  • Payers, reimbursement specialists and health-technology assessment experts
  • Clinical investigators and intravascular-imaging specialists
  • Cardiac nurses and PCI pathway coordinators